Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.

Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JC, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE, Hayashi H, MARIPOSA Investigators

Open source

DOI
10.1056/nejmoa2403614
Published
2024 Oct 24
Container
The New England journal of medicine
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2403614,
  title = {Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.},
  author = {Cho BC and Lu S and Felip E and Spira AI and Girard N and Lee JS and Lee SH and Ostapenko Y and Danchaivijitr P and Liu B and Alip A and Korbenfeld E and Mourão Dias J and Besse B and Lee KH and Xiong H and How SH and Cheng Y and Chang GC and Yoshioka H and Yang JC and Thomas M and Nguyen D and Ou SI and Mukhedkar S and Prabhash K and D'Arcangelo M and Alatorre-Alexander J and Vázquez Limón JC and Alves S and Stroyakovskiy D and Peregudova M and Şendur MAN and Yazici O and Califano R and Gutiérrez Calderón V and de Marinis F and Passaro A and Kim SW and Gadgeel SM and Xie J and Sun T and Martinez M and Ennis M and Fennema E and Daksh M and Millington D and Leconte I and Iwasawa R and Lorenzini P and Baig M and Shah S and Bauml JM and Shreeve SM and Sethi S and Knoblauch RE and Hayashi H and MARIPOSA Investigators},
  year = {2024},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa2403614},
  url = {https://doi.org/10.1056/nejmoa2403614}
}

RIS

TY  - JOUR
TI  - Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
AU  - Cho BC
AU  - Lu S
AU  - Felip E
AU  - Spira AI
AU  - Girard N
AU  - Lee JS
AU  - Lee SH
AU  - Ostapenko Y
AU  - Danchaivijitr P
AU  - Liu B
AU  - Alip A
AU  - Korbenfeld E
AU  - Mourão Dias J
AU  - Besse B
AU  - Lee KH
AU  - Xiong H
AU  - How SH
AU  - Cheng Y
AU  - Chang GC
AU  - Yoshioka H
AU  - Yang JC
AU  - Thomas M
AU  - Nguyen D
AU  - Ou SI
AU  - Mukhedkar S
AU  - Prabhash K
AU  - D'Arcangelo M
AU  - Alatorre-Alexander J
AU  - Vázquez Limón JC
AU  - Alves S
AU  - Stroyakovskiy D
AU  - Peregudova M
AU  - Şendur MAN
AU  - Yazici O
AU  - Califano R
AU  - Gutiérrez Calderón V
AU  - de Marinis F
AU  - Passaro A
AU  - Kim SW
AU  - Gadgeel SM
AU  - Xie J
AU  - Sun T
AU  - Martinez M
AU  - Ennis M
AU  - Fennema E
AU  - Daksh M
AU  - Millington D
AU  - Leconte I
AU  - Iwasawa R
AU  - Lorenzini P
AU  - Baig M
AU  - Shah S
AU  - Bauml JM
AU  - Shreeve SM
AU  - Sethi S
AU  - Knoblauch RE
AU  - Hayashi H
AU  - MARIPOSA Investigators
PY  - 2024
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa2403614
UR  - https://doi.org/10.1056/nejmoa2403614
ER  -

APA

BC, C., S, L., E, F., AI, S., N, G., JS, L., SH, L., Y, O., P, D., B, L., A, A., E, K., J, M. D., B, B., KH, L., H, X., SH, H., Y, C., GC, C., H, Y., JC, Y., M, T., D, N., SI, O., S, M., K, P., M, D., J, A., JC, V. L., S, A., D, S., M, P., MAN, Ş., O, Y., R, C., V, G. C., F, D. M., A, P., SW, K., SM, G., J, X., T, S., M, M., M, E., E, F., M, D., D, M., I, L., R, I., P, L., M, B., S, S., JM, B., SM, S., S, S., RE, K., H, H., & Investigators, M. (2024). Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.. The New England journal of medicine. https://doi.org/10.1056/nejmoa2403614

Source records